CLINICAL_TRIALS
withdrawal
· 2012-12-17
Clinical Trial Update: Inhaled Amikacin Treatment for Nontuberculous Mycobacterial Lung Disease [Phase 2]
Summary
A Phase 2 clinical trial evaluating inhaled amikacin for pulmonary non-tuberculous mycobacterial lung disease has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Samsung Medical Center | Conditions: Pulmonary Non-tuberculous Mycobacterial Lung Disease | Phase 2 | Status: WITHDRAWN